Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 34

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

271

HTML

1987

Figures (1-3)

228

Tables (1-3)

211

Sum=2697

Sep 14, 2009 (publication date) through Nov 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Articles

World J Gastroenterol. Sep 14, 2009; 15(34): 4278-4283
Published online Sep 14, 2009. doi: 10.3748/wjg.15.4278

Full Size Figure Download Figure

Figure 1 Carcinoembryonic antigen (CEA) serum level before and 2 mo after the beginning of the treatment.

Citation: Ghiringhelli F, Guiu B, Chauffert B, Ladoire S. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World J Gastroenterol 2009; 15(34): 4278-4283
URL: https://www.wjgnet.com/1007-9327/full/v15/i34/4278.htm
DOI: https://dx.doi.org/10.3748/wjg.15.4278